Zhang M X, Tan W, Zhang R X, Tian Y L, Gao H M, Gao Z, Zhang N, Zhao J Q, Jia Y F, Wang Y S
Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Nursing Department of Shandong Medical College, Jinan, Shandong, China.
Genet Mol Res. 2014 Oct 27;13(4):8657-60. doi: 10.4238/2014.October.27.5.
The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. The first patient was alive at 8 years with alternative conventional chemotherapy and gefitinib, and the second patient was alive at long-term follow-up with conventional chemotherapy and gefitinib or erlotinib. Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC.
表皮生长因子受体（EGFR）抑制剂吉非替尼和厄洛替尼在晚期非小细胞肺癌（NSCLC）治疗中有效，但患者的中位生存期较短。在此，我们描述了2例接受传统化疗并交替使用吉非替尼或厄洛替尼作为二线治疗的NSCLC患者。第一例患者在接受交替的传统化疗和吉非替尼治疗后存活了8年，第二例患者在接受传统化疗并联合吉非替尼或厄洛替尼治疗后长期随访存活。吉非替尼、厄洛替尼和传统化疗联合使用可对NSCLC进行令人满意的治疗。
